Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 2Prostatic Neoplasms 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Advanced or Metastatic Solid Malignancies 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1

Interventions

Injections 24pembrolizumab 13toripalimab 12tislelizumab 9Gemcitabine 7Cisplatin 7Carboplatin 6atezolizumab 5Nivolumab 5Irinotecan 5Pemetrexed 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Docetaxel 4Cetuximab 4trastuzumab deruxtecan 3spartalizumab 3cediranib 3Paclitaxel 3PM 01183 3Capecitabine 3sintilimab 2olaparib 2lenvatinib 2glumetinib 2camrelizumab 2apatinib 2Therapeutics 2Midazolam 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumor × sitravatinib × Clear all
NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡